×
收藏-健康|会员访问记?/h3>
| |页标题Q? | |
×
注册健康|用?/h3>
| ??名： | ||
|---|---|---|
| ?p?人： | ?nbsp; 别： | |
| ?nbsp; 码： | ||
| 重复密码Q?/th> | ||
| ?sh)子邮箱Q?/th> | ||
| 邮箱验证码： | ||
| 固定?sh)话Q?/th> | ||
| ?nbsp; 真： | ||
| ?nbsp; 机： | ||
| 单位名称Q?/th> | ||
| 通信地址Q?/th> | ||
| 首选栏目： | ||
| 我已l认真阅dƈ同意《健L(fng)服务条款?/a> | ||
| 定注册 | ||
FDA q发三䆾癌症ȝ药开发相x?/H1>
作者：xuezhe 来源Q互联网 点击敎ͼ0 更新旉Q?022-10-21 17:26:30
相关q接
Sodium thiosulfate has been approved by the FDA to reduce hearing loss in children caused by chemotherapySodium thiosulfate has been approved by the FDA to reduce hearing loss in children caused by chemotherapy
FDA 如何在x资料中提交真实世界数据和证据发布定稿指南
FDA再「变脸」，药企如何在矛盾中安n立命
FDA approves ibrutinib for chronic graft-versus-host disease in children 1 year older
FDA Issues Drug Statement, Mercks Hypoglycemic Drug Sitagliptin Detected Potential Carcinogen
提前4个月QFDA批准ADC药物EnhertuQDS-8201Q用于治疗「HER2低表达」^腺癌(zhn)者，市场有望扩大5倍！
FDA再次拒绝pimavanserinȝ阿尔Ҏ(gu)v默症相关_病新适应症上市申?/a>
Upadatinibs launch accelerated: Crohns disease has simultaneously submitted marketing applications in FDA&EMA
FDA 如何在x资料中提交真实世界数据和证据发布定稿指南
FDA再「变脸」，药企如何在矛盾中安n立命
FDA approves ibrutinib for chronic graft-versus-host disease in children 1 year older
FDA Issues Drug Statement, Mercks Hypoglycemic Drug Sitagliptin Detected Potential Carcinogen
提前4个月QFDA批准ADC药物EnhertuQDS-8201Q用于治疗「HER2低表达」^腺癌(zhn)者，市场有望扩大5倍！
FDA再次拒绝pimavanserinȝ阿尔Ҏ(gu)v默症相关_病新适应症上市申?/a>
Upadatinibs launch accelerated: Crohns disease has simultaneously submitted marketing applications in FDA&EMA